Abstract In addition to promoting erythropoiesis, week in CRF rats [4] . The increase in arterial blood chronic administration of epoetin frequently increases pressure usually accompanies an increase in haematoblood pressure, ameliorates uraemic platelet dysfunc-crit. This temporal association has led to the common tion, enhances platelet production and elevates resting belief that epoetin-induced hypertension is due to the and stimulated cytosolic [Ca2+]. In addition, in vivo increase in erythrocyte mass and concentration. and in vitro studies have demonstrated that epoetin However, subsequent studies have provided strong may modify production and activity of certain vaso-evidence against this proposition and have implicated active factors and may promote vascular cell growth. a number of other mechanisms. Many of the latter effects of epoetin appear to be unrelated to the associated erythropoietic action of the hormone and must, therefore, involve other Role of haematocrit mechanisms. The present article is intended to provide a brief overview of the effects of epoetin on vascular It has been thought that correction of anaemia with and haemostatic systems.
Introduction
is marked by volume and pressure dysregulation. However, in a series of studies in rats with CRF, we The availability of epoetin has greatly enhanced the showed that epoetin-induced hypertension is clearly management of anaemia of chronic renal failure unrelated to the increase in haematocrit. To dissect the (CRF ) and has substantially improved quality of life effect of haematocrit from the effect of epoetin per se, in the dialysis population. However, chronic adminis-we administered epoetin for 6 weeks to CRF animals tration of epoetin can lead to an increase in arterial with adequate iron stores and CRF rats with iron blood pressure in patients and experimental animals depletion. Blood pressure increased markedly and with CRF. Recognition of this phenomenon during equally in both groups, despite the fact that anaemia the clinical trials of epoetin nearly a decade ago has persisted in the iron-depleted group but was corrected triggered a large series of clinical and laboratory in those with adequate iron stores [4] . Moreover, in studies to discern the mechanism(s) by which epoetin another group of CRF rats, we successfully corrected therapy increases blood pressure. This communication the anaemia with multiple small blood transfusions is intended to provide a brief overview of the effects but found no significant increase in arterial blood of epoetin on vascular and haemostatic systems.
pressure during the study period. Based on these observations, we concluded that the change in blood pressure was related to repeated administration of Effect on arterial blood pressure epoetin as opposed to the associated increase in haematocrit [4] . These observations are consistent with our After the initiation of maintenance epoetin therapy, earlier study of a group of iron-deficient anaemic CRF blood pressure frequently increases within several patients who, while receiving a constant dosage of weeks to months in CRF patients [1] [2] [3] and after~1 epoetin throughout the study period, showed no further increase in blood pressure despite significant increases in haematocrits with iron repletion [9] . It is However, the occurrence of severe hypertension with tive response to a-1 adrenergic agonist, methoxamine, epoetin therapy despite persistent anaemia in ironin tail arterial rings pre-incubated in various epoetin deficient CRF rats, and the lack of hypertension despite concentrations or rings prepared from epoetin-treated correction of anaemia with multiple blood transfusions CRF rats [4, 13] .
[4], tend to exclude this possibility. Interestingly, epoetin therapy has been shown to cause NO resistance, as evidenced in epoetin-treated animals by a reduced Renin-angiotensin system hypotensive response in vivo and a reduced vasorelaxChronic administration of epoetin in rats has been ation response in vitro to the administration of shown to increase kidney and aorta expression of renin NO-donor, sodium nitroprusside [4] . Recently, del mRNA and angiotensinogen mRNA [14] . However, Castillo et al. have demonstrated that the occurrence epoetin therapy did not significantly change plasma of hypertension with epoetin therapy in rats is accomrenin or angiotensin [14] . Based on these observations, panied by an increase in urinary excretion of nitrate the authors concluded that epoetin-induced hyperten-and nitrite, suggesting enhanced NO production [23] . sion may be due to enhanced tissue renin-angiotensin The presence of hypertension despite elevated NO activity. In a series of in vivo and in vitro studies, we production that is reported by these authors is consistfound no significant modification in pressor response ent with the NO resistance in epoetin-treated animals to angiotensin II with chronic or acute epoetin adminis-reported by Vaziri et al. [4] . tration [4, 13] . At high concentrations, epoetin has been shown to exert a fast-acting vasopressor action on rat mesenteric and renal resistance vessels, as well as rat caudal artery Role of vasopressin and atrial natriuretic peptide (ANP) rings in vitro [13, 26 ] . However, no such effect was found using rings prepared from the rabbit aorta, Based on the available clinical and experimental studies, epoetin therapy does not appear to affect directly which is a conduit artery [17] . Although epoetin can cause direct vasoconstriction in muscular arteries in the plasma concentration of these hormones [10,20,21]. However, through expansion of blood volume, epoetin vitro, it has no fast-acting effect on blood pressure in vivo in either rats or humans [13, 21] . We have shown may increase ANP release.
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in vivo, despite a demonstrable vasoconstrictive action proliferation and DNA synthesis in vitro. [27] . with epoetin therapy is due to correction of the defect-15. Carlini R, Obialo CI, Rothstein M. Intravenous erythropoietin ive Ca2+ signalling in the platelets [4] . In addition to 
